ACE2 News and Research

RSS
A new polymersome-based SARS-CoV-2 nanovaccine elicits robust immunity

A new polymersome-based SARS-CoV-2 nanovaccine elicits robust immunity

Study demonstrates that the main creators of SARS-CoV-2 mutations are vaccine-suppressed

Study demonstrates that the main creators of SARS-CoV-2 mutations are vaccine-suppressed

Experimental evidence that ADAM17 inhibition prevents severe COVID-19

Experimental evidence that ADAM17 inhibition prevents severe COVID-19

Researchers develop model for SARS-CoV-2 fusion intermediate that helps membrane fusion

Researchers develop model for SARS-CoV-2 fusion intermediate that helps membrane fusion

Study of antiviral nutraceutical phenolics against SARS-CoV-2 main protease

Study of antiviral nutraceutical phenolics against SARS-CoV-2 main protease

A host of mutations could compromise COVID-19 vaccines and antibody therapies

A host of mutations could compromise COVID-19 vaccines and antibody therapies

Researchers develop broad-spectrum SARS-CoV-2 RBD-based vaccine

Researchers develop broad-spectrum SARS-CoV-2 RBD-based vaccine

ACE2 homology in laboratory and wild animals

ACE2 homology in laboratory and wild animals

Could Zebrafish larvae be a novel animal model for SARS-CoV-2?

Could Zebrafish larvae be a novel animal model for SARS-CoV-2?

Nanobody cocktails neutralize SARS-CoV-2 and variants

Nanobody cocktails neutralize SARS-CoV-2 and variants

Broadly cross-reactive antibody to SARS-CoV-2 RBD with robust resistance to mutational escape

Broadly cross-reactive antibody to SARS-CoV-2 RBD with robust resistance to mutational escape

P681 mutation has little impact on transmissibility in the SARS-CoV-2 UK variant, finds study

P681 mutation has little impact on transmissibility in the SARS-CoV-2 UK variant, finds study

Researchers provide ultrastructural details of SARS-CoV-2-infected respiratory epithelial cells

Researchers provide ultrastructural details of SARS-CoV-2-infected respiratory epithelial cells

Researchers explore an inhalable SARS-CoV-2 nanobody therapy

Researchers explore an inhalable SARS-CoV-2 nanobody therapy

Could N protein-based COVID-19 vaccines hinder SARS-CoV-2's NK cell inhibition?

Could N protein-based COVID-19 vaccines hinder SARS-CoV-2's NK cell inhibition?

COVID19's cytokine storm ushers in a local complement storm in the lungs

COVID19's cytokine storm ushers in a local complement storm in the lungs

The role and ancestry of the SARS-CoV-2 spike protein glycan shield

The role and ancestry of the SARS-CoV-2 spike protein glycan shield

L452R and Y453F SARS-CoV-2 mutations increase transmission and evade immunity

L452R and Y453F SARS-CoV-2 mutations increase transmission and evade immunity

Previously approved drugs starting points for COVID-19 therapeutics

Previously approved drugs starting points for COVID-19 therapeutics

New polypeptide could provide universal protection against coronaviruses

New polypeptide could provide universal protection against coronaviruses